Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos and Arthrogen Pen Rheumatoid Arthritis Gene Therapy Target-Discovery Deal

NEW YORK, March 30 (GenomeWeb News) - Galapagos has signed a three-year agreement with Arthrogen to discover gene therapy targets related to rheumatoid arthritis, Galapagos said today.

 

Under the terms of the agreement, Galapagos' service division, BioFocus, will discover, characterize, and validate candidate protein targets in return for an upfront payment, R&D funding, and milestone payments provided by Arthrogen, the companies said.

 

Total revenues associated with a qualifying target may exceed €7.5 million ($9 million), the companies added.

 

Arthrogen is a joint venture of the Dubai Bone & Joint Center and the Academic Medical Center in Amsterdam.